Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Breast Cancer

  Free Subscription


Articles published in BMC Cancer

Retrieve available abstracts of 190 articles:
HTML format
Text format



Single Articles


    September 2018
  1. JOUALI F, Marchoudi N, Talbi S, Bilal B, et al
    Detection of PIK3/AKT pathway in Moroccan population with triple negative breast cancer.
    BMC Cancer. 2018;18:900.
    PubMed     Text format     Abstract available


  2. ELWOOD JM, Tawfiq E, TinTin S, Marshall RJ, et al
    Development and validation of a new predictive model for breast cancer survival in New Zealand and comparison to the Nottingham prognostic index.
    BMC Cancer. 2018;18:897.
    PubMed     Text format     Abstract available


  3. XIONG Z, Deng G, Wang J, Li X, et al
    Could local surgery improve survival in de novo stage IV breast cancer?
    BMC Cancer. 2018;18:885.
    PubMed     Text format     Abstract available


  4. VENTURELLI E, Orenti A, Fabricio ASC, Garrone G, et al
    Correction to: Observational study on the prognostic value of testosterone and adiposity in postmenopausal estrogen receptor positive breast cancer patients.
    BMC Cancer. 2018;18:876.
    PubMed     Text format     Abstract available


  5. FAJKA-BOJA R, Marton A, Toth A, Blazso P, et al
    Increased insulin-like growth factor 1 production by polyploid adipose stem cells promotes growth of breast cancer cells.
    BMC Cancer. 2018;18:872.
    PubMed     Text format     Abstract available


  6. KIRKHAM AA, Paterson DI, Prado CM, Mackey JM, et al
    Rationale and design of the Caloric Restriction and Exercise protection from Anthracycline Toxic Effects (CREATE) study: a 3-arm parallel group phase II randomized controlled trial in early breast cancer.
    BMC Cancer. 2018;18:864.
    PubMed     Text format     Abstract available


  7. DUIVON M, Perrier J, Joly F, Licaj I, et al
    Impact of breast cancer on prospective memory functioning assessed by virtual reality and influence of sleep quality and hormonal therapy: PROSOM-K study.
    BMC Cancer. 2018;18:866.
    PubMed     Text format     Abstract available


  8. NIAZI MKK, Senaras C, Pennell M, Arole V, et al
    Relationship between the Ki67 index and its area based approximation in breast cancer.
    BMC Cancer. 2018;18:867.
    PubMed     Text format     Abstract available


  9. BROEDERS MJM, Allgood P, Duffy SW, Hofvind S, et al
    The impact of mammography screening programmes on incidence of advanced breast cancer in Europe: a literature review.
    BMC Cancer. 2018;18:860.
    PubMed     Text format     Abstract available


    August 2018
  10. HEIL J, Sinn P, Richter H, Pfob A, et al
    RESPONDER - diagnosis of pathological complete response by vacuum-assisted biopsy after neoadjuvant chemotherapy in breast Cancer - a multicenter, confirmative, one-armed, intra-individually-controlled, open, diagnostic trial.
    BMC Cancer. 2018;18:851.
    PubMed     Text format     Abstract available


  11. HULTSCH S, Kankainen M, Paavolainen L, Kovanen RM, et al
    Association of tamoxifen resistance and lipid reprogramming in breast cancer.
    BMC Cancer. 2018;18:850.
    PubMed     Text format     Abstract available


  12. FUMET JD, Wickre M, Jacquot JP, Bizollon MH, et al
    Successfully treatment by eribulin in visceral crisis: a case of lymphangitic carcinomatosis from metastatic breast cancer.
    BMC Cancer. 2018;18:839.
    PubMed     Text format     Abstract available


  13. MENG LL, Wang JL, Xu SP, Zu LD, et al
    Low serum gastrin associated with ER(+) breast cancer development via inactivation of CCKBR/ERK/P65 signaling.
    BMC Cancer. 2018;18:824.
    PubMed     Text format     Abstract available


  14. WANG B, Li D, Rodriguez-Juarez R, Farfus A, et al
    A suppressive role of guanine nucleotide-binding protein subunit beta-4 inhibited by DNA methylation in the growth of anti-estrogen resistant breast cancer cells.
    BMC Cancer. 2018;18:817.
    PubMed     Text format     Abstract available


  15. DENARD B, Jiang S, Peng Y, Ye J, et al
    CREB3L1 as a potential biomarker predicting response of triple negative breast cancer to doxorubicin-based chemotherapy.
    BMC Cancer. 2018;18:813.
    PubMed     Text format     Abstract available


  16. AXELSSON U, Ryden L, Johnsson P, Eden P, et al
    A multicenter study investigating the molecular fingerprint of psychological resilience in breast cancer patients: study protocol of the SCAN-B resilience study.
    BMC Cancer. 2018;18:789.
    PubMed     Text format     Abstract available


  17. BAEYENS-FERNANDEZ JA, Molina-Portillo E, Pollan M, Rodriguez-Barranco M, et al
    Trends in incidence, mortality and survival in women with breast cancer from 1985 to 2012 in Granada, Spain: a population-based study.
    BMC Cancer. 2018;18:781.
    PubMed     Text format     Abstract available


    July 2018
  18. VIALA M, Chiba A, Thezenas S, Delmond L, et al
    Impact of vitamin D on pathological complete response and survival following neoadjuvant chemotherapy for breast cancer: a retrospective study.
    BMC Cancer. 2018;18:770.
    PubMed     Text format     Abstract available


  19. BEELEN K, Opdam M, Severson T, Koornstra R, et al
    Mitotic count can predict tamoxifen benefit in postmenopausal breast cancer patients while Ki67 score cannot.
    BMC Cancer. 2018;18:761.
    PubMed     Text format     Abstract available


  20. LEE M, Tayyari F, Pinnaduwage D, Bayani J, et al
    Tumoral BRD4 expression in lymph node-negative breast cancer: association with T-bet+ tumor-infiltrating lymphocytes and disease-free survival.
    BMC Cancer. 2018;18:750.
    PubMed     Text format     Abstract available


  21. GIBBONS JA, Kanwar JR, Kanwar RK
    Correction to: Iron-free and iron-saturated bovine lactoferrin inhibit survivin expression and differentially modulate apoptosis in breast cancer.
    BMC Cancer. 2018;18:749.
    PubMed     Text format     Abstract available


  22. RETHORST CD, Hamann HA, Carmody TJ, Sharp KJ, et al
    The Promoting Activity in Cancer Survivors (PACES) trial: a multiphase optimization of strategy approach to increasing physical activity in breast cancer survivors.
    BMC Cancer. 2018;18:744.
    PubMed     Text format     Abstract available


  23. VASMATZIS G, Wang X, Smadbeck JB, Murphy SJ, et al
    Chromoanasynthesis is a common mechanism that leads to ERBB2 amplifications in a cohort of early stage HER2(+) breast cancer samples.
    BMC Cancer. 2018;18:738.
    PubMed     Text format     Abstract available


  24. LAMBERT LK, Balneaves LG, Howard AF, Chia SK, et al
    Understanding adjuvant endocrine therapy persistence in breast Cancer survivors.
    BMC Cancer. 2018;18:732.
    PubMed     Text format     Abstract available


  25. NUSHTAEVA AA, Stepanov GA, Semenov DV, Juravlev ES, et al
    Characterization of primary normal and malignant breast cancer cell and their response to chemotherapy and immunostimulatory agents.
    BMC Cancer. 2018;18:728.
    PubMed     Text format     Abstract available


  26. HE Y, Tan EH, Wong ALA, Tan CC, et al
    Improving medication adherence with adjuvant aromatase inhibitor in women with breast cancer: study protocol of a randomised controlled trial to evaluate the effect of short message service (SMS) reminder.
    BMC Cancer. 2018;18:727.
    PubMed     Text format     Abstract available


  27. YOON YN, Choe MH, Jung KY, Hwang SG, et al
    MASTL inhibition promotes mitotic catastrophe through PP2A activation to inhibit cancer growth and radioresistance in breast cancer cells.
    BMC Cancer. 2018;18:716.
    PubMed     Text format     Abstract available


  28. SLAOUI M, Zoure AA, Mouh FZ, Bensouda Y, et al
    Outcome of inflammatory breast cancer in Moroccan patients: clinical, molecular and pathological characteristics of 219 cases from the National Oncology Institute (INO).
    BMC Cancer. 2018;18:713.
    PubMed     Text format     Abstract available


  29. REAL SAS, Parveen F, Rehman AU, Khan MA, et al
    Aberrant Promoter Methylation of YAP Gene and its Subsequent Downregulation in Indian Breast Cancer Patients.
    BMC Cancer. 2018;18:711.
    PubMed     Text format     Abstract available


  30. RANGEL N, Fortunati N, Osella-Abate S, Annaratone L, et al
    FOXA1 and AR in invasive breast cancer: new findings on their co-expression and impact on prognosis in ER-positive patients.
    BMC Cancer. 2018;18:703.
    PubMed     Text format     Abstract available


    June 2018
  31. ZOPPINO FCM, Guerrero-Gimenez ME, Castro GN, Ciocca DR, et al
    Comprehensive transcriptomic analysis of heat shock proteins in the molecular subtypes of human breast cancer.
    BMC Cancer. 2018;18:700.
    PubMed     Text format     Abstract available


  32. HAYASHIDA T, Jinno H, Mori K, Sato H, et al
    Phase II trial of eribulin mesylate as a first- or second-line treatment for locally advanced or metastatic breast cancer: a multicenter, single-arm trial.
    BMC Cancer. 2018;18:701.
    PubMed     Text format     Abstract available


  33. VAN GELDERMALSEN M, Quek LE, Turner N, Freidman N, et al
    Benzylserine inhibits breast cancer cell growth by disrupting intracellular amino acid homeostasis and triggering amino acid response pathways.
    BMC Cancer. 2018;18:689.
    PubMed     Text format     Abstract available


  34. EHLERS DK, Fanning J, Salerno EA, Aguinaga S, et al
    Replacing sedentary time with physical activity or sleep: effects on cancer-related cognitive impairment in breast cancer survivors.
    BMC Cancer. 2018;18:685.
    PubMed     Text format     Abstract available


  35. GREGOIRE C, Nicolas H, Bragard I, Delevallez F, et al
    Efficacy of a hypnosis-based intervention to improve well-being during cancer: a comparison between prostate and breast cancer patients.
    BMC Cancer. 2018;18:677.
    PubMed     Text format     Abstract available


  36. INOUE K, Ninomiya J, Saito T, Kimizuka K, et al
    Induction therapy with paclitaxel and bevacizumab followed by switch maintenance therapy with eribulin in Japanese patients with HER2-negative metastatic breast cancer: a multicenter, collaborative, open-label, phase II clinical study for the SBCCSG 3
    BMC Cancer. 2018;18:671.
    PubMed     Text format     Abstract available


  37. LI Y, Du Y, Sun T, Xue H, et al
    PD-1 blockade in combination with zoledronic acid to enhance the antitumor efficacy in the breast cancer mouse model.
    BMC Cancer. 2018;18:669.
    PubMed     Text format     Abstract available


  38. LI R, Xiao C, Liu H, Huang Y, et al
    Effects of local anesthetics on breast cancer cell viability and migration.
    BMC Cancer. 2018;18:666.
    PubMed     Text format     Abstract available


  39. XU H, Xu Y, Ouyang T, Li J, et al
    Low expression of RECQL is associated with poor prognosis in Chinese breast cancer patients.
    BMC Cancer. 2018;18:662.
    PubMed     Text format     Abstract available


  40. LOFTEROD T, Mortensen ES, Nalwoga H, Wilsgaard T, et al
    Impact of pre-diagnostic triglycerides and HDL-cholesterol on breast cancer recurrence and survival by breast cancer subtypes.
    BMC Cancer. 2018;18:654.
    PubMed     Text format     Abstract available


  41. VENTURELLI E, Orenti A, Fabricio ASC, Garrone G, et al
    Observational study on the prognostic value of testosterone and adiposity in postmenopausal estrogen receptor positive breast cancer patients.
    BMC Cancer. 2018;18:651.
    PubMed     Text format     Abstract available


  42. DUSENGIMANA JMV, Hategekimana V, Borg R, Hedt-Gauthier B, et al
    Pregnancy-associated breast cancer in rural Rwanda: the experience of the Butaro Cancer Center of Excellence.
    BMC Cancer. 2018;18:634.
    PubMed     Text format     Abstract available


    May 2018
  43. NATTENMULLER CJ, Kriegsmann M, Sookthai D, Fortner RT, et al
    Obesity as risk factor for subtypes of breast cancer: results from a prospective cohort study.
    BMC Cancer. 2018;18:616.
    PubMed     Text format     Abstract available


  44. WHITNEY J, Corredor G, Janowczyk A, Ganesan S, et al
    Quantitative nuclear histomorphometry predicts oncotype DX risk categories for early stage ER+ breast cancer.
    BMC Cancer. 2018;18:610.
    PubMed     Text format     Abstract available


  45. MADHU KRISHNA B, Chaudhary S, Mishra DR, Naik SK, et al
    Estrogen receptor alpha dependent regulation of estrogen related receptor beta and its role in cell cycle in breast cancer.
    BMC Cancer. 2018;18:607.
    PubMed     Text format     Abstract available


  46. HOUSE CD, Grajales V, Ozaki M, Jordan E, et al
    IKappaKappaepsilon cooperates with either MEK or non-canonical NF-kB driving growth of triple-negative breast cancer cells in different contexts.
    BMC Cancer. 2018;18:595.
    PubMed     Text format     Abstract available


  47. MUDDUWA L, Peiris H, Gunasekara S, Abeysiriwardhana D, et al
    KIBRA; a novel biomarker predicting recurrence free survival of breast cancer patients receiving adjuvant therapy.
    BMC Cancer. 2018;18:589.
    PubMed     Text format     Abstract available


  48. FORTE L, Turdo F, Ghirelli C, Aiello P, et al
    The PDGFRbeta/ERK1/2 pathway regulates CDCP1 expression in triple-negative breast cancer.
    BMC Cancer. 2018;18:586.
    PubMed     Text format     Abstract available


  49. BUCZEK E, Denslow A, Mateuszuk L, Proniewski B, et al
    Alterations in NO- and PGI2- dependent function in aorta in the orthotopic murine model of metastatic 4T1 breast cancer: relationship with pulmonary endothelial dysfunction and systemic inflammation.
    BMC Cancer. 2018;18:582.
    PubMed     Text format     Abstract available


  50. PARASHAR S, Cheishvili D, Mahmood N, Arakelian A, et al
    DNA methylation signatures of breast cancer in peripheral T-cells.
    BMC Cancer. 2018;18:574.
    PubMed     Text format     Abstract available


  51. BATES JP, Derakhshandeh R, Jones L, Webb TJ, et al
    Mechanisms of immune evasion in breast cancer.
    BMC Cancer. 2018;18:556.
    PubMed     Text format     Abstract available


  52. BANYS-PALUCHOWSKI M, Fehm T, Janni W, Aktas B, et al
    Elevated serum RAS p21 is an independent prognostic factor in metastatic breast cancer.
    BMC Cancer. 2018;18:541.
    PubMed     Text format     Abstract available


  53. DOUGAN MM, Li Y, Chu LW, Haile RW, et al
    Metabolomic profiles in breast cancer:a pilot case-control study in the breast cancer family registry.
    BMC Cancer. 2018;18:532.
    PubMed     Text format     Abstract available


  54. NAIK A, Al-Yahyaee A, Abdullah N, Sam JE, et al
    Neuropilin-1 promotes the oncogenic Tenascin-C/integrin beta3 pathway and modulates chemoresistance in breast cancer cells.
    BMC Cancer. 2018;18:533.
    PubMed     Text format     Abstract available


  55. PENAULT-LLORCA F, Filleron T, Asselain B, Baehner FL, et al
    The 21-gene Recurrence Score(R) assay predicts distant recurrence in lymph node-positive, hormone receptor-positive, breast cancer patients treated with adjuvant sequential epirubicin- and docetaxel-based or epirubicin-based chemotherapy (PACS-01 tria
    BMC Cancer. 2018;18:526.
    PubMed     Text format     Abstract available


  56. LI W, Xu L, Che X, Li H, et al
    C-Cbl reverses HER2-mediated tamoxifen resistance in human breast cancer cells.
    BMC Cancer. 2018;18:507.
    PubMed     Text format     Abstract available


  57. DI GIROLAMO C, Walters S, Benitez Majano S, Rachet B, et al
    Characteristics of patients with missing information on stage: a population-based study of patients diagnosed with colon, lung or breast cancer in England in 2013.
    BMC Cancer. 2018;18:492.
    PubMed     Text format     Abstract available


    April 2018
  58. HUANG S, Murphy L, Xu W
    Genes and functions from breast cancer signatures.
    BMC Cancer. 2018;18:473.
    PubMed     Text format     Abstract available


  59. FERNANDO A, Jayarajah U, Prabashani S, Fernando EA, et al
    Incidence trends and patterns of breast cancer in Sri Lanka: an analysis of the national cancer database.
    BMC Cancer. 2018;18:482.
    PubMed     Text format     Abstract available


  60. LIUTKAUSKIENE S, Grizas S, Jureniene K, Suipyte J, et al
    Retrospective analysis of the impact of anthracycline dose reduction and chemotherapy delays on the outcomes of early breast cancer molecular subtypes.
    BMC Cancer. 2018;18:453.
    PubMed     Text format     Abstract available


  61. PODRALSKA M, Ziolkowska-Suchanek I, Zurawek M, Dzikiewicz-Krawczyk A, et al
    Genetic variants in ATM, H2AFX and MRE11 genes and susceptibility to breast cancer in the polish population.
    BMC Cancer. 2018;18:452.
    PubMed     Text format     Abstract available


  62. JIN J, Gao Y, Zhang J, Wang L, et al
    Incidence, pattern and prognosis of brain metastases in patients with metastatic triple negative breast cancer.
    BMC Cancer. 2018;18:446.
    PubMed     Text format     Abstract available


  63. SEMMLINGER A, von Schoenfeldt V, Wolf V, Meuter A, et al
    EP3 (prostaglandin E2 receptor 3) expression is a prognostic factor for progression-free and overall survival in sporadic breast cancer.
    BMC Cancer. 2018;18:431.
    PubMed     Text format     Abstract available


  64. XIAO B, Chen L, Ke Y, Hang J, et al
    Identification of methylation sites and signature genes with prognostic value for luminal breast cancer.
    BMC Cancer. 2018;18:405.
    PubMed     Text format     Abstract available


  65. HILLER L, Dunn JA, Loi S, Vallier AL, et al
    Adjuvant trastuzumab duration trials in HER2 positive breast cancer - what results would be practice-changing? Persephone investigator questionnaire prior to primary endpoint results.
    BMC Cancer. 2018;18:391.
    PubMed     Text format     Abstract available


  66. VAN DER WAAL D, Verbeek ALM, Broeders MJM
    Breast density and breast cancer-specific survival by detection mode.
    BMC Cancer. 2018;18:386.
    PubMed     Text format     Abstract available


  67. PHI XA, Tagliafico A, Houssami N, Greuter MJW, et al
    Digital breast tomosynthesis for breast cancer screening and diagnosis in women with dense breasts - a systematic review and meta-analysis.
    BMC Cancer. 2018;18:380.
    PubMed     Text format     Abstract available


  68. HUNG CH, Chen FM, Lin YC, Tsai ML, et al
    Altered monocyte differentiation and macrophage polarization patterns in patients with breast cancer.
    BMC Cancer. 2018;18:366.
    PubMed     Text format     Abstract available


  69. LIU Y, Du Y, Hu X, Zhao L, et al
    Up-regulation of ceRNA TINCR by SP1 contributes to tumorigenesis in breast cancer.
    BMC Cancer. 2018;18:367.
    PubMed     Text format     Abstract available


    March 2018
  70. AN X, Xu F, Luo R, Zheng Q, et al
    The prognostic significance of topoisomerase II alpha protein in early stage luminal breast cancer.
    BMC Cancer. 2018;18:331.
    PubMed     Text format     Abstract available


  71. CHEN J, Zhu Y, Zhang W, Peng X, et al
    Delphinidin induced protective autophagy via mTOR pathway suppression and AMPK pathway activation in HER-2 positive breast cancer cells.
    BMC Cancer. 2018;18:342.
    PubMed     Text format     Abstract available


  72. DITTUS KL, Harvey JR, Bunn JY, Kokinda ND, et al
    Impact of a behaviorally-based weight loss intervention on parameters of insulin resistance in breast cancer survivors.
    BMC Cancer. 2018;18:351.
    PubMed     Text format     Abstract available


  73. BRONTE G, Rocca A, Ravaioli S, Puccetti M, et al
    Androgen receptor in advanced breast cancer: is it useful to predict the efficacy of anti-estrogen therapy?
    BMC Cancer. 2018;18:348.
    PubMed     Text format     Abstract available


  74. XU Y, Yang X, Wang T, Yang L, et al
    Knockdown delta-5-desaturase in breast cancer cells that overexpress COX-2 results in inhibition of growth, migration and invasion via a dihomo-gamma-linolenic acid peroxidation dependent mechanism.
    BMC Cancer. 2018;18:330.
    PubMed     Text format     Abstract available


  75. AHN SG, Cha YJ, Bae SJ, Yoon C, et al
    Comparisons of tumor-infiltrating lymphocyte levels and the 21-gene recurrence score in ER-positive/HER2-negative breast cancer.
    BMC Cancer. 2018;18:320.
    PubMed     Text format     Abstract available


  76. WANG YA, Jian JW, Hung CF, Peng HP, et al
    Germline breast cancer susceptibility gene mutations and breast cancer outcomes.
    BMC Cancer. 2018;18:315.
    PubMed     Text format     Abstract available


  77. MOODLEY J, Cairncross L, Naiker T, Constant D, et al
    From symptom discovery to treatment - women's pathways to breast cancer care: a cross-sectional study.
    BMC Cancer. 2018;18:312.
    PubMed     Text format     Abstract available


  78. ZHANG JJ, Shu H, Hu SS, Yu Y, et al
    Relationship between time elapsed since completion of radiotherapy and quality of life of patients with breast cancer.
    BMC Cancer. 2018;18:305.
    PubMed     Text format     Abstract available


  79. MENSAH KB, Oosthuizen F, Bonsu AB
    Cancer awareness among community pharmacist: a systematic review.
    BMC Cancer. 2018;18:299.
    PubMed     Text format     Abstract available


  80. MULLER V, Clemens M, Jassem J, Al-Sakaff N, et al
    Long-term trastuzumab (Herceptin(R)) treatment in a continuation study of patients with HER2-positive breast cancer or HER2-positive gastric cancer.
    BMC Cancer. 2018;18:295.
    PubMed     Text format     Abstract available


  81. HARDI H, Melki R, Boughaleb Z, El Harroudi T, et al
    Significant association between ERCC2 and MTHR polymorphisms and breast cancer susceptibility in Moroccan population: genotype and haplotype analysis in a case-control study.
    BMC Cancer. 2018;18:292.
    PubMed     Text format     Abstract available


  82. MCANENA PF, McGuire A, Ramli A, Curran C, et al
    Correction to: Breast cancer subtype discordance: impact on post-recurrence survival and potential treatment options.
    BMC Cancer. 2018;18:282.
    PubMed     Text format     Abstract available


  83. DAVID D, Surendran A, Thulaseedharan JV, Nair AS, et al
    Regulation of CNKSR2 protein stability by the HECT E3 ubiquitin ligase Smurf2, and its role in breast cancer progression.
    BMC Cancer. 2018;18:284.
    PubMed     Text format     Abstract available


  84. DIERSSEN-SOTOS T, Palazuelos-Calderon C, Jimenez-Moleon JJ, Aragones N, et al
    Reproductive risk factors in breast cancer and genetic hormonal pathways: a gene-environment interaction in the MCC-Spain project.
    BMC Cancer. 2018;18:280.
    PubMed     Text format     Abstract available


  85. SONG Q, Chen Q, Wang Q, Yang L, et al
    ATF-3/miR-590/GOLPH3 signaling pathway regulates proliferation of breast cancer.
    BMC Cancer. 2018;18:255.
    PubMed     Text format     Abstract available


  86. NAAB TJ, Gautam A, Ricks-Santi L, Esnakula AK, et al
    MYC amplification in subtypes of breast cancers in African American women.
    BMC Cancer. 2018;18:274.
    PubMed     Text format     Abstract available


  87. YANG L, Wang J, Cheng J, Wang Y, et al
    Quality assurance target for community-based breast cancer screening in China: a model simulation.
    BMC Cancer. 2018;18:261.
    PubMed     Text format     Abstract available


  88. VONDELING GT, Menezes GL, Dvortsin EP, Jansman FGA, et al
    Burden of early, advanced and metastatic breast cancer in The Netherlands.
    BMC Cancer. 2018;18:262.
    PubMed     Text format     Abstract available


  89. ENGEL C, Rhiem K, Hahnen E, Loibl S, et al
    Prevalence of pathogenic BRCA1/2 germline mutations among 802 women with unilateral triple-negative breast cancer without family cancer history.
    BMC Cancer. 2018;18:265.
    PubMed     Text format     Abstract available


  90. ANWAR SL, Tampubolon G, Van Hemelrijck M, Hutajulu SH, et al
    Determinants of cancer screening awareness and participation among Indonesian women.
    BMC Cancer. 2018;18:208.
    PubMed     Text format     Abstract available


  91. SANKATSING VDV, Fracheboud J, de Munck L, Broeders MJM, et al
    Detection and interval cancer rates during the transition from screen-film to digital mammography in population-based screening.
    BMC Cancer. 2018;18:256.
    PubMed     Text format     Abstract available


    February 2018
  92. ISFOSS BL, Holmqvist B, Sand E, Forsell J, et al
    Stellate cells and mesenchymal stem cells in benign mammary stroma are associated with risk factors for breast cancer - an observational study.
    BMC Cancer. 2018;18:230.
    PubMed     Text format     Abstract available


  93. SOOTICHOTE R, Thuwajit P, Singsuksawat E, Warnnissorn M, et al
    Compound A attenuates toll-like receptor 4-mediated paclitaxel resistance in breast cancer and melanoma through suppression of IL-8.
    BMC Cancer. 2018;18:231.
    PubMed     Text format     Abstract available


  94. GAVA F, Rigal L, Mondesert O, Pesce E, et al
    Gap junctions contribute to anchorage-independent clustering of breast cancer cells.
    BMC Cancer. 2018;18:221.
    PubMed     Text format     Abstract available


  95. JAASKELAINEN A, Soini Y, Jukkola-Vuorinen A, Auvinen P, et al
    High-level cytoplasmic claudin 3 expression is an independent predictor of poor survival in triple-negative breast cancer.
    BMC Cancer. 2018;18:223.
    PubMed     Text format     Abstract available


  96. HOU MF, Chen PM, Chu PY
    LGR5 overexpression confers poor relapse-free survival in breast cancer patients.
    BMC Cancer. 2018;18:219.
    PubMed     Text format     Abstract available


  97. MCANENA PF, Brown JA, Ramli A, Curran C, et al
    Breast cancer subtype discordance: impact on post-recurrence survival and potential treatment options.
    BMC Cancer. 2018;18:203.
    PubMed     Text format     Abstract available


  98. HUEBNER H, Fasching PA, Gumbrecht W, Jud S, et al
    Filtration based assessment of CTCs and CellSearch(R) based assessment are both powerful predictors of prognosis for metastatic breast cancer patients.
    BMC Cancer. 2018;18:204.
    PubMed     Text format     Abstract available


  99. WESTVIK AS, Weedon-Fekjaer H, Maehlen J, Liestol K, et al
    Evaluating different breast tumor progression models using screening data.
    BMC Cancer. 2018;18:209.
    PubMed     Text format     Abstract available


  100. SIRISENA ND, Adeyemo A, Kuruppu AI, Neththikumara N, et al
    Genetic determinants of sporadic breast cancer in Sri Lankan women.
    BMC Cancer. 2018;18:180.
    PubMed     Text format     Abstract available


  101. NOJIMA M, Iwasaki M, Kasuga Y, Yokoyama S, et al
    Correlation between global methylation level of peripheral blood leukocytes and serum C reactive protein level modified by MTHFR polymorphism: a cross-sectional study.
    BMC Cancer. 2018;18:184.
    PubMed     Text format     Abstract available


  102. KODAIRA M, Yonemori K, Shimoi T, Yoshida A, et al
    Prognostic impact of presumed breast or ovarian cancer among patients with unfavorable-subset cancer of unknown primary site.
    BMC Cancer. 2018;18:176.
    PubMed     Text format     Abstract available


  103. IBRAHIM M, Yadav S, Ogunleye F, Zakalik D, et al
    Male BRCA mutation carriers: clinical characteristics and cancer spectrum.
    BMC Cancer. 2018;18:179.
    PubMed     Text format     Abstract available


  104. KJALLQUIST U, Erlandsson R, Tobin NP, Alkodsi A, et al
    Exome sequencing of primary breast cancers with paired metastatic lesions reveals metastasis-enriched mutations in the A-kinase anchoring protein family (AKAPs).
    BMC Cancer. 2018;18:174.
    PubMed     Text format     Abstract available


  105. AL DOSSARY R, Alkharsah KR, Kussaibi H
    Prevalence of Mouse Mammary Tumor Virus (MMTV)-like sequences in human breast cancer tissues and adjacent normal breast tissues in Saudi Arabia.
    BMC Cancer. 2018;18:170.
    PubMed     Text format     Abstract available


  106. LAFOURCADE A, His M, Baglietto L, Boutron-Ruault MC, et al
    Factors associated with breast cancer recurrences or mortality and dynamic prediction of death using history of cancer recurrences: the French E3N cohort.
    BMC Cancer. 2018;18:171.
    PubMed     Text format     Abstract available


  107. NGUYEN-DUMONT T, Teo ZL, Hammet F, Roberge A, et al
    Is RNASEL:p.Glu265* a modifier of early-onset breast cancer risk for carriers of high-risk mutations?
    BMC Cancer. 2018;18:165.
    PubMed     Text format     Abstract available


  108. CORTET M, Bertaut A, Molinie F, Bara S, et al
    Trends in molecular subtypes of breast cancer: description of incidence rates between 2007 and 2012 from three French registries.
    BMC Cancer. 2018;18:161.
    PubMed     Text format     Abstract available


  109. LAM WWT, Kwong A, Suen D, Tsang J, et al
    Factors predicting patient satisfaction in women with advanced breast cancer: a prospective study.
    BMC Cancer. 2018;18:162.
    PubMed     Text format     Abstract available


  110. LIM JA, Oh CS, Yoon TG, Lee JY, et al
    The effect of propofol and sevoflurane on cancer cell, natural killer cell, and cytotoxic T lymphocyte function in patients undergoing breast cancer surgery: an in vitro analysis.
    BMC Cancer. 2018;18:159.
    PubMed     Text format     Abstract available


  111. ABDEL-RAZEQ H, Al-Omari A, Zahran F, Arun B, et al
    Germline BRCA1/BRCA2 mutations among high risk breast cancer patients in Jordan.
    BMC Cancer. 2018;18:152.
    PubMed     Text format     Abstract available


  112. PENSABENE M, Stanzione B, Cerillo I, Ciancia G, et al
    It is no longer the time to disregard thyroid metastases from breast cancer: a case report and review of the literature.
    BMC Cancer. 2018;18:146.
    PubMed     Text format     Abstract available


  113. ALUNNI-FABBRONI M, Majunke L, Trapp EK, Tzschaschel M, et al
    Whole blood microRNAs as potential biomarkers in post-operative early breast cancer patients.
    BMC Cancer. 2018;18:141.
    PubMed     Text format     Abstract available


  114. TRAORE BM, El Fakir S, Charaka H, Benaicha N, et al
    Evolution of quality of life in patients with breast cancer during the first year of follow-up in Morocco.
    BMC Cancer. 2018;18:109.
    PubMed     Text format     Abstract available


  115. NOVAK J, Besic N, Dzodic R, Gazic B, et al
    Pre-operative and intra-operative detection of axillary lymph node metastases in 108 patients with invasive lobular breast cancer undergoing mastectomy.
    BMC Cancer. 2018;18:137.
    PubMed     Text format     Abstract available


  116. BEGUINOT M, Dauplat MM, Kwiatkowski F, Lebouedec G, et al
    Analysis of tumour-infiltrating lymphocytes reveals two new biologically different subgroups of breast ductal carcinoma in situ.
    BMC Cancer. 2018;18:129.
    PubMed     Text format     Abstract available


  117. KAEWKANGSADAN V, Verma C, Eremin JM, Cowley G, et al
    Tumour-draining axillary lymph nodes in patients with large and locally advanced breast cancers undergoing neoadjuvant chemotherapy (NAC): the crucial contribution of immune cells (effector, regulatory) and cytokines (Th1, Th2) to immune-mediated tumo
    BMC Cancer. 2018;18:123.
    PubMed     Text format     Abstract available


    January 2018
  118. EVANS RL, Pottala JV, Nagata S, Egland KA, et al
    Longitudinal autoantibody responses against tumor-associated antigens decrease in breast cancer patients according to treatment modality.
    BMC Cancer. 2018;18:119.
    PubMed     Text format     Abstract available


  119. HSIEH E, Wang Q, Zhang R, Niu X, et al
    Vertebral fractures among breast cancer survivors in China: a cross-sectional study of prevalence and health services gaps.
    BMC Cancer. 2018;18:104.
    PubMed     Text format     Abstract available


  120. FRERES P, Bouznad N, Servais L, Josse C, et al
    Variations of circulating cardiac biomarkers during and after anthracycline-containing chemotherapy in breast cancer patients.
    BMC Cancer. 2018;18:102.
    PubMed     Text format     Abstract available


  121. RICCIARDI GRR, Russo A, Franchina T, Schifano S, et al
    Efficacy of T-DM1 for leptomeningeal and brain metastases in a HER2 positive metastatic breast cancer patient: new directions for systemic therapy - a case report and literature review.
    BMC Cancer. 2018;18:97.
    PubMed     Text format     Abstract available


  122. HAQUE I, Ghosh A, Acup S, Banerjee S, et al
    Leptin-induced ER-alpha-positive breast cancer cell viability and migration is mediated by suppressing CCN5-signaling via activating JAK/AKT/STAT-pathway.
    BMC Cancer. 2018;18:99.
    PubMed     Text format     Abstract available


  123. DE LIGT KM, Witteveen A, Siesling S, Steuten LMG, et al
    Shifting breast cancer surveillance from current hospital setting to a community based setting: a cost-effectiveness study.
    BMC Cancer. 2018;18:96.
    PubMed     Text format     Abstract available


  124. PARK VY, Kim EK, Kim MJ, Moon HJ, et al
    Breast magnetic resonance imaging for surveillance of women with a personal history of breast cancer: outcomes stratified by interval between definitive surgery and surveillance MR imaging.
    BMC Cancer. 2018;18:91.
    PubMed     Text format     Abstract available


  125. PARK JS, Lee ST, Nam EJ, Han JW, et al
    Variants of cancer susceptibility genes in Korean BRCA1/2 mutation-negative patients with high risk for hereditary breast cancer.
    BMC Cancer. 2018;18:83.
    PubMed     Text format     Abstract available


  126. ELWOOD JM, Tin Tin S, Kuper-Hommel M, Lawrenson R, et al
    Obesity and breast cancer outcomes in chemotherapy patients in New Zealand - a population-based cohort study.
    BMC Cancer. 2018;18:76.
    PubMed     Text format     Abstract available


  127. BERNAL-ESTEVEZ DA, Garcia O, Sanchez R, Parra-Lopez CA, et al
    Monitoring the responsiveness of T and antigen presenting cell compartments in breast cancer patients is useful to predict clinical tumor response to neoadjuvant chemotherapy.
    BMC Cancer. 2018;18:77.
    PubMed     Text format     Abstract available


  128. YU SJ, Yang L, Hong Q, Kuang XY, et al
    MicroRNA-200a confers chemoresistance by antagonizing TP53INP1 and YAP1 in human breast cancer.
    BMC Cancer. 2018;18:74.
    PubMed     Text format     Abstract available


  129. GARCIA-GUTIERREZ S, Orive M, Sarasqueta C, Legarreta MJ, et al
    Health services research in patients with breast cancer (CAMISS-prospective): study protocol for an observational prospective study.
    BMC Cancer. 2018;18:54.
    PubMed     Text format     Abstract available


  130. DALL P, Koch T, Gohler T, Selbach J, et al
    Trastuzumab without chemotherapy in the adjuvant treatment of breast cancer: subgroup results from a large observational study.
    BMC Cancer. 2018;18:51.
    PubMed     Text format     Abstract available


  131. TIN TIN S, Elwood JM, Brown C, Sarfati D, et al
    Ethnic disparities in breast cancer survival in New Zealand: which factors contribute?
    BMC Cancer. 2018;18:58.
    PubMed     Text format     Abstract available


  132. URRU SAM, Gallus S, Bosetti C, Moi T, et al
    Clinical and pathological factors influencing survival in a large cohort of triple-negative breast cancer patients.
    BMC Cancer. 2018;18:56.
    PubMed     Text format     Abstract available


  133. KUMAR D, Haldar S, Gorain M, Kumar S, et al
    Epoxyazadiradione suppresses breast tumor growth through mitochondrial depolarization and caspase-dependent apoptosis by targeting PI3K/Akt pathway.
    BMC Cancer. 2018;18:52.
    PubMed     Text format     Abstract available


  134. LOVITT CJ, Shelper TB, Avery VM
    Doxorubicin resistance in breast cancer cells is mediated by extracellular matrix proteins.
    BMC Cancer. 2018;18:41.
    PubMed     Text format     Abstract available


  135. PARK E, Yoon J, Choi EK, Kim IR, et al
    A train the trainer program for healthcare professionals tasked with providing psychosocial support to breast cancer survivors.
    BMC Cancer. 2018;18:45.
    PubMed     Text format     Abstract available


  136. LOUHICHI T, Saad H, Dhiab MB, Ziadi S, et al
    Stromal CD10 expression in breast cancer correlates with tumor invasion and cancer stem cell phenotype.
    BMC Cancer. 2018;18:49.
    PubMed     Text format     Abstract available


  137. HERNANDEZ RK, Wade SW, Reich A, Pirolli M, et al
    Incidence of bone metastases in patients with solid tumors: analysis of oncology electronic medical records in the United States.
    BMC Cancer. 2018;18:44.
    PubMed     Text format     Abstract available


  138. NZEANGUNG BA, Biwole ME, Kadia BM, Bechem NN, et al
    Evolutionary aspects of non-metastatic breast cancer after primary treatment in a sub-Saharan African setting: a 16-year retrospective review at the Douala general hospital, Cameroon.
    BMC Cancer. 2018;18:32.
    PubMed     Text format     Abstract available


  139. NARRANDES S, Huang S, Murphy L, Xu W, et al
    The exploration of contrasting pathways in Triple Negative Breast Cancer (TNBC).
    BMC Cancer. 2018;18:22.
    PubMed     Text format     Abstract available


  140. ZHOU K, He X, Huo L, An J, et al
    Development of the body image self-rating questionnaire for breast cancer (BISQ-BC) for Chinese mainland patients.
    BMC Cancer. 2018;18:19.
    PubMed     Text format     Abstract available


  141. PATRICIO M, Pereira J, Crisostomo J, Matafome P, et al
    Using Resistin, glucose, age and BMI to predict the presence of breast cancer.
    BMC Cancer. 2018;18:29.
    PubMed     Text format     Abstract available


  142. LI M, Li A, Zhou S, Xu Y, et al
    Heterogeneity of PD-L1 expression in primary tumors and paired lymph node metastases of triple negative breast cancer.
    BMC Cancer. 2018;18:4.
    PubMed     Text format     Abstract available


    December 2017
  143. LYNGE E, Bak M, von Euler-Chelpin M, Kroman N, et al
    Outcome of breast cancer screening in Denmark.
    BMC Cancer. 2017;17:897.
    PubMed     Text format     Abstract available


  144. HUANG LH, Chung HY, Su HM
    Docosahexaenoic acid reduces sterol regulatory element binding protein-1 and fatty acid synthase expression and inhibits cell proliferation by inhibiting pAkt signaling in a human breast cancer MCF-7 cell line.
    BMC Cancer. 2017;17:890.
    PubMed     Text format     Abstract available


  145. ASANO Y, Kashiwagi S, Goto W, Takada K, et al
    Prediction of survival after neoadjuvant chemotherapy for breast cancer by evaluation of tumor-infiltrating lymphocytes and residual cancer burden.
    BMC Cancer. 2017;17:888.
    PubMed     Text format     Abstract available


  146. MERCOGLIANO MF, Inurrigarro G, De Martino M, Venturutti L, et al
    Invasive micropapillary carcinoma of the breast overexpresses MUC4 and is associated with poor outcome to adjuvant trastuzumab in HER2-positive breast cancer.
    BMC Cancer. 2017;17:895.
    PubMed     Text format     Abstract available


  147. LIU LN, Lin YC, Miaskowski C, Chen SC, et al
    Association between changes in body fat and disease progression after breast cancer surgery is moderated by menopausal status.
    BMC Cancer. 2017;17:863.
    PubMed     Text format     Abstract available


  148. KRISHNAN K, Baglietto L, Stone J, McLean C, et al
    Mammographic density and risk of breast cancer by tumor characteristics: a case-control study.
    BMC Cancer. 2017;17:859.
    PubMed     Text format     Abstract available


  149. KUMARI K, Keshari S, Sengupta D, Sabat SC, et al
    Transcriptome analysis of genes associated with breast cancer cell motility in response to Artemisinin treatment.
    BMC Cancer. 2017;17:858.
    PubMed     Text format     Abstract available


  150. WU Y, Zhang N, Yang Q
    The prognosis of invasive micropapillary carcinoma compared with invasive ductal carcinoma in the breast: a meta-analysis.
    BMC Cancer. 2017;17:839.
    PubMed     Text format     Abstract available


  151. GAO D, Cazares LH, Fish EN
    CCL5-CCR5 interactions modulate metabolic events during tumor onset to promote tumorigenesis.
    BMC Cancer. 2017;17:834.
    PubMed     Text format     Abstract available


  152. BAXTER GD, Liu L, Petrich S, Gisselman AS, et al
    Low level laser therapy (Photobiomodulation therapy) for breast cancer-related lymphedema: a systematic review.
    BMC Cancer. 2017;17:833.
    PubMed     Text format     Abstract available


  153. PHAM TND, Perez White BE, Zhao H, Mortazavi F, et al
    Protein kinase C alpha enhances migration of breast cancer cells through FOXC2-mediated repression of p120-catenin.
    BMC Cancer. 2017;17:832.
    PubMed     Text format     Abstract available


  154. KO H, Shin J, Lee JE, Nam SJ, et al
    Comparison of the association of mammographic density and clinical factors with ductal carcinoma in situ versus invasive ductal breast cancer in Korean women.
    BMC Cancer. 2017;17:821.
    PubMed     Text format     Abstract available


  155. OCHNIK AM, Baxter RC
    Insulin-like growth factor receptor and sphingosine kinase are prognostic and therapeutic targets in breast cancer.
    BMC Cancer. 2017;17:820.
    PubMed     Text format     Abstract available


  156. HE D, Fang Y, Gunter MJ, Xu D, et al
    Incidence of breast cancer in Chinese women exposed to the 1959-1961 great Chinese famine.
    BMC Cancer. 2017;17:824.
    PubMed     Text format     Abstract available


  157. IIZUMI S, Shimoi T, Tsushita N, Bun S, et al
    Efficacy and safety of eribulin in patients with locally advanced or metastatic breast cancer not meeting trial eligibility criteria: a retrospective study.
    BMC Cancer. 2017;17:819.
    PubMed     Text format     Abstract available


  158. THOMAS ET, Del Mar C, Glasziou P, Wright G, et al
    Prevalence of incidental breast cancer and precursor lesions in autopsy studies: a systematic review and meta-analysis.
    BMC Cancer. 2017;17:808.
    PubMed     Text format     Abstract available


  159. SENGAL AT, Haj-Mukhtar NS, Elhaj AM, Bedri S, et al
    Immunohistochemistry defined subtypes of breast cancer in 678 Sudanese and Eritrean women; hospitals based case series.
    BMC Cancer. 2017;17:804.
    PubMed     Text format     Abstract available


    November 2017
  160. KARTHIK GM, Rantalainen M, Stalhammar G, Lovrot J, et al
    Intra-tumor heterogeneity in breast cancer has limited impact on transcriptomic-based molecular profiling.
    BMC Cancer. 2017;17:802.
    PubMed     Text format     Abstract available


  161. QATTAN A, Intabli H, Alkhayal W, Eltabache C, et al
    Robust expression of tumor suppressor miRNA's let-7 and miR-195 detected in plasma of Saudi female breast cancer patients.
    BMC Cancer. 2017;17:799.
    PubMed     Text format     Abstract available


  162. GIORDANO L, Gallo F, Petracci E, Chiorino G, et al
    The ANDROMEDA prospective cohort study: predictive value of combined criteria to tailor breast cancer screening and new opportunities from circulating markers: study protocol.
    BMC Cancer. 2017;17:785.
    PubMed     Text format     Abstract available


  163. TAKESHITA T, Yamamoto Y, Yamamoto-Ibusuki M, Sueta A, et al
    Prevalence of ESR1 E380Q mutation in tumor tissue and plasma from Japanese breast cancer patients.
    BMC Cancer. 2017;17:786.
    PubMed     Text format     Abstract available


  164. WONG XY, Chong KJ, van Til JA, Wee HL, et al
    A qualitative study on Singaporean women's views towards breast cancer screening and Single Nucleotide Polymorphisms (SNPs) gene testing to guide personalised screening strategies.
    BMC Cancer. 2017;17:776.
    PubMed     Text format     Abstract available


  165. SHIROIWA T, Fukuda T, Shimozuma K, Mouri M, et al
    Cost-effectiveness analysis of the introduction of S-1 therapy for first-line metastatic breast cancer treatment in Japan: results from the randomized phase III SELECT BC trial.
    BMC Cancer. 2017;17:773.
    PubMed     Text format     Abstract available


  166. ISAKOVA J, Talaibekova E, Aldasheva N, Vinnikov D, et al
    The association of polymorphic markers Arg399Gln of XRCC1 gene, Arg72Pro of TP53 gene and T309G of MDM2 gene with breast cancer in Kyrgyz females.
    BMC Cancer. 2017;17:758.
    PubMed     Text format     Abstract available


  167. SAVCI-HEIJINK CD, Halfwerk H, Koster J, Van de Vijver MJ, et al
    Association between gene expression profile of the primary tumor and chemotherapy response of metastatic breast cancer.
    BMC Cancer. 2017;17:755.
    PubMed     Text format     Abstract available


  168. LI J, Lai Y, Ma J, Liu Y, et al
    miR-17-5p suppresses cell proliferation and invasion by targeting ETV1 in triple-negative breast cancer.
    BMC Cancer. 2017;17:745.
    PubMed     Text format     Abstract available


  169. KHAN UT, Walker AJ, Baig S, Card TR, et al
    Venous thromboembolism and mortality in breast cancer: cohort study with systematic review and meta-analysis.
    BMC Cancer. 2017;17:747.
    PubMed     Text format     Abstract available


  170. ERNST J, Mehnert A, Dietz A, Hornemann B, et al
    Perceived stigmatization and its impact on quality of life - results from a large register-based study including breast, colon, prostate and lung cancer patients.
    BMC Cancer. 2017;17:741.
    PubMed     Text format     Abstract available


  171. MINICHILLO S, Gallelli I, Barbieri E, Cubelli M, et al
    Trastuzumab resumption after extremely severe cardiotoxicity in metastatic breast cancer patient: a case report.
    BMC Cancer. 2017;17:722.
    PubMed     Text format     Abstract available


  172. QUINTERO M, Adamoski D, Reis LMD, Ascencao CFR, et al
    Guanylate-binding protein-1 is a potential new therapeutic target for triple-negative breast cancer.
    BMC Cancer. 2017;17:727.
    PubMed     Text format     Abstract available


  173. GOHR K, Hamacher A, Engelke LH, Kassack MU, et al
    Inhibition of PI3K/Akt/mTOR overcomes cisplatin resistance in the triple negative breast cancer cell line HCC38.
    BMC Cancer. 2017;17:711.
    PubMed     Text format     Abstract available


  174. LANZ HL, Saleh A, Kramer B, Cairns J, et al
    Therapy response testing of breast cancer in a 3D high-throughput perfused microfluidic platform.
    BMC Cancer. 2017;17:709.
    PubMed     Text format     Abstract available


    October 2017
  175. REPO H, Gurvits N, Loyttyniemi E, Nykanen M, et al
    PTTG1-interacting protein (PTTG1IP/PBF) predicts breast cancer survival.
    BMC Cancer. 2017;17:705.
    PubMed     Text format     Abstract available


  176. D'ALOISIO AA, Nichols HB, Hodgson ME, Deming-Halverson SL, et al
    Validity of self-reported breast cancer characteristics in a nationwide cohort of women with a family history of breast cancer.
    BMC Cancer. 2017;17:692.
    PubMed     Text format     Abstract available


  177. KIM HM, Lee J, Koo JS
    Clinicopathological and prognostic significance of programmed death ligand-1 expression in breast cancer: a meta-analysis.
    BMC Cancer. 2017;17:690.
    PubMed     Text format     Abstract available


  178. JAHN B, Rochau U, Kurzthaler C, Hubalek M, et al
    Personalized treatment of women with early breast cancer: a risk-group specific cost-effectiveness analysis of adjuvant chemotherapy accounting for companion prognostic tests OncotypeDX and Adjuvant!Online.
    BMC Cancer. 2017;17:685.
    PubMed     Text format     Abstract available


  179. LYSZCZARZ B, Nojszewska E
    Productivity losses and public finance burden attributable to breast cancer in Poland, 2010-2014.
    BMC Cancer. 2017;17:676.
    PubMed     Text format     Abstract available


    September 2017
  180. ABHYANKAR N, Hoskins KF, Abern MR, Calip GS, et al
    Descriptive characteristics of prostate cancer in patients with a history of primary male breast cancer - a SEER analysis.
    BMC Cancer. 2017;17:659.
    PubMed     Text format     Abstract available


  181. REITHMEIER A, Panizza E, Krumpel M, Orre LM, et al
    Tartrate-resistant acid phosphatase (TRAP/ACP5) promotes metastasis-related properties via TGFbeta2/TbetaR and CD44 in MDA-MB-231 breast cancer cells.
    BMC Cancer. 2017;17:650.
    PubMed     Text format     Abstract available


  182. REYNOLDS KL, Bedard PL, Lee SH, Lin CC, et al
    A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer.
    BMC Cancer. 2017;17:646.
    PubMed     Text format     Abstract available


  183. HUSSAIN AR, Siraj AK, Ahmed M, Bu R, et al
    XIAP over-expression is an independent poor prognostic marker in Middle Eastern breast cancer and can be targeted to induce efficient apoptosis.
    BMC Cancer. 2017;17:640.
    PubMed     Text format     Abstract available


  184. DEB S, Gorringe KL, Pang JB, Byrne DJ, et al
    BRCA2 carriers with male breast cancer show elevated tumour methylation.
    BMC Cancer. 2017;17:641.
    PubMed     Text format     Abstract available


    May 2017
  185. VOELS B, Wang L, Sens DA, Garrett SH, et al
    The unique C- and N-terminal sequences of Metallothionein isoform 3 mediate growth inhibition and Vectorial active transport in MCF-7 cells.
    BMC Cancer. 2017;17:369.
    PubMed     Text format     Abstract available


  186. DEMOOR-GOLDSCHMIDT C, Drui D, Doutriaux I, Michel G, et al
    A French national breast and thyroid cancer screening programme for survivors of childhood, adolescent and young adult (CAYA) cancers - DeNaCaPST programme.
    BMC Cancer. 2017;17:326.
    PubMed     Text format     Abstract available


  187. BOGAN D, Meile L, El Bastawisy A, Yousef HF, et al
    The role of BRCA1-IRIS in the development and progression of triple negative breast cancers in Egypt: possible link to disease early lesion.
    BMC Cancer. 2017;17:329.
    PubMed     Text format     Abstract available


  188. CHIN-QUEE K, Donahue HJ
    MDA-MET-conditioned-medium augments the chemoattractant-dependent migration of MDA-MET cells towards hFOB-conditioned medium and increases collagenase activity.
    BMC Cancer. 2017;17:324.
    PubMed     Text format     Abstract available


    April 2017
  189. JUNG SY, Sobel EM, Papp JC, Zhang ZF, et al
    Effect of genetic variants and traits related to glucose metabolism and their interaction with obesity on breast and colorectal cancer risk among postmenopausal women.
    BMC Cancer. 2017;17:290.
    PubMed     Text format     Abstract available


    March 2017
  190. BERNTSEN S, Aaronson NK, Buffart L, Borjeson S, et al
    Design of a randomized controlled trial of physical training and cancer (Phys-Can) - the impact of exercise intensity on cancer related fatigue, quality of life and disease outcome.
    BMC Cancer. 2017;17:218.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: